An Act to amend and reenact §§ 38.2-3407.5:1 and 38.2-3407.5:2 of the Code of Virginia, relating to health insurance; coverage for contraceptive drugs and devices.
HB1182 amends Virginia’s insurance code to expand and clarify contraceptive coverage requirements in health plans. The bill requires insurers, health maintenance organizations, and subscription contract providers that already cover outpatient prescription drugs to offer coverage for FDA-approved contraceptive drugs and devices, including certain over-the-counter products. It also bars unequal copayments or coinsurance for contraceptive benefits and requires coverage of at least one therapeutically equivalent contraceptive option without cost-sharing, while allowing cost-sharing on other equivalent versions unless a provider determines a specific product is medically necessary.
The bill further limits administrative barriers by prohibiting burdensome restrictions or delays, including requiring a prescription for over-the-counter contraceptives or extra formal requests beyond standard pharmacy or exceptions processes. It also requires insurers to provide clear written information about contraceptive coverage on request and on their websites. The measure preserves some existing limits: it does not force plans that do not otherwise cover prescription drugs to add such coverage, allows closed formularies so long as they include certain contraceptive categories, and excludes experimental or non-FDA-approved products and several categories of short-term or government-related coverage.
HB1182 also amends the separate provision on hormonal contraceptives to require health benefit plans that cover them to provide up to a 12-month supply when dispensed at one time, and to provide point-of-sale coverage without cost-sharing for over-the-counter hormonal contraceptives at in-network pharmacies. It prohibits utilization controls or medical management that would reduce access below a 12-month supply, while clarifying that providers are not required to prescribe that amount at once and that coverage can still be used for non-contraceptive medical purposes. The bill applies to relevant policies and plans issued, delivered, or renewed on or after January 1, 2027.
The bill’s impact is to broaden contraceptive access in Virginia’s regulated health insurance market and to standardize coverage rules for both prescription and over-the-counter contraceptive products. It affects insurers, health carriers, HMOs, and similar health benefit plans by imposing coverage, cost-sharing, disclosure, and supply requirements, while leaving certain plan types and federal or short-term coverage arrangements outside its scope.
The overall sentiment appears supportive but divided. The bill advanced through both chambers and was ultimately enacted, but several committee and floor votes were close, especially in the House and Senate, indicating meaningful partisan or policy disagreement. The main points of contention were likely the mandate to cover contraceptives, limits on cost-sharing and utilization management, and the extent to which insurers must cover over-the-counter products and extended supplies without additional barriers.
HB1182 amends §§ 38.2-3407.5:1 and 38.2-3407.5:2 of the Code of Virginia to expand mandated contraceptive coverage in health insurance and health benefit plans. It requires covered plans to offer FDA-approved contraceptive drugs and devices, including certain over-the-counter products, prohibits discriminatory cost-sharing, requires at least one therapeutically equivalent option without cost-sharing, and mandates up to a 12-month supply of hormonal contraceptives under qualifying plans. The bill also adds disclosure and anti-delay requirements and applies to policies and plans issued, delivered, or renewed on or after January 1, 2027, while preserving exemptions for certain short-term, limited, and government-related coverage.
The bill appears to have had generally favorable support sufficient for enactment, but with notable opposition. It passed both chambers and survived gubernatorial recommendations, yet several votes were relatively close, suggesting the measure was politically contested. Support likely centered on expanding access and reducing barriers to contraception, while opposition likely focused on insurance mandates, cost-sharing restrictions, and the scope of required coverage.
The main contention was over whether the state should require insurers to cover contraceptives, including over-the-counter products, without cost-sharing and with limited administrative hurdles. Opponents likely objected to the insurance mandate, the requirement to cover a 12-month supply, and restrictions on utilization management, while supporters emphasized access, affordability, and continuity of care. Another point of debate was the bill’s exceptions and carve-outs, including closed formularies, medical-necessity overrides, and exclusions for certain plan types and non-FDA-approved products.